Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
This article was originally published in Pharmaceutical Approvals Monthly
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.
You may also be interested in...
Trials in Crohn’s disease and ulcerative colitis are going with plans for filing in both indications. Meanwhile, Takeda’s blockbuster GI drug Prevacid goes generic in May.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.